



**Martin Dreyling**

**Contact**

Martin Dreyling

## Publications (2)

Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadiant S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). *EClinicalMedicine* 2023; 64:102221.

Klapper W, Möller P, Barth T, Muller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken J, Wacker H, Unterhalt M, Hiddemann W, Dreyling M, Stein H, Loddenkemper C, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd H, Cabeçadas J, Campo E, Cogliatti S, Hansmann M, Klün P, Kodet R, Krivolapov Y, for the European MCL Network. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. *Journal of hematopathology* 2009

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)